Figure 2.

Therapeutic response to ICI is dependent on immune preconditioning. After sacrifice, thyroids were isolated from all animals and histological sections were stained with H&E. The presence or absence of PTC was assessed by a pathologist blinded to study group assignment. The number of animals with PTC present or absent is reported for each study arm.A) Within each study arm, results are broken down by treatment group (anti-TIM-3 Ab, anti-PD-1 Ab, anti-LAG-3 Ab, or control). Analysis via the chi-square test showed that the frequency of PTC was different across experimental groups in the context of concomitant IET (p=0.018) but not in the context of no IET (p=0.761) or pre-existing IET (p=0.725). B) All animals treated with ICI are combined within the same group. Also in this analysis the frequency of PTC was lower in presence of concomitant IET (p=0.002) but not in the presence of pre-existing IET (p=0.387) or in the absence of IET (p=0.426). ICI, immune checkpoint inhibitor; IET, iodine exacerbated thyroiditis; LAG-3, lymphocyte activation gene 3; PTC, papillary thyroid cancer; TIM-3, T-cell immunoglobulin and mucin domain 3.